Ann: Chairman's Address to Shareholders, page-2

looks like they may have to bring in an equity partner ( with deeper pockets). Many of us suggested thesame over the years as we watched the cash burn and the slow uptake of the trials. So the question is ... where does Siements stand in al of this. They had from Day 1 been providing some technical input so they clearly were interested in seeing if the technology worked or not ( and it seems to work) so logically you have to wonder why we have heard nothing about any further engagement and/or some form of partnership taking the clinical trials into the USA, which was the next planned location for clinical trialling. I just dont get it.